Radical cystectomy for bladder cancer in solid organ transplant recipients
Jazyk angličtina Země Itálie Médium print
Typ dokumentu časopisecké články, multicentrická studie
PubMed
40298345
DOI
10.23736/s2724-6051.25.06130-0
PII: S2724-6051.25.06130-0
Knihovny.cz E-zdroje
- MeSH
- cystektomie * metody MeSH
- lidé středního věku MeSH
- lidé MeSH
- lymfadenektomie MeSH
- míra přežití MeSH
- nádory močového měchýře * chirurgie mortalita patologie MeSH
- pooperační komplikace epidemiologie MeSH
- příjemce transplantátu MeSH
- retrospektivní studie MeSH
- senioři MeSH
- transplantace orgánů * MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
BACKGROUND: Solid organ transplant recipients (SOTRs) face higher cancer risk because of immunosuppressive therapy used to prevent organ rejection. We hypothesized that SOTRs treated with radical cystectomy (RC) and pelvic lymph-node dissection (PLND) for bladder cancer (UBC) might have worse survival outcomes compared to non-SOTRs. This study aims to assess survival outcomes of SOTRs treated with RC and PLND for UBC compared to non-SOTRs. METHODS: A retrospective analysis of 645 patients treated with RC and PLND for UBC, originating from our multicenter cooperation program (2002-2022), stratified in two groups according to previous solid organ transplantation. Co-primary endpoints were OS and CSS, assessed using mixed-effects Cox-analysis. Secondary endpoints included postoperative complications, readmission-rates, operation time, estimated blood loss and length of stay. RESULTS: Of the 361 patients analyzed (median follow-up: 17 months), 23 were SOTRs. SOTRs exhibited lower 12-month (70% vs. 80%) and 24-month (36% vs. 68%) OS-rates compared to non-SOTRs (P=0.011). Corresponding CSS-rates were also lower for SOTRs at 12 (81% vs. 85%) and 24 months (55% vs. 76%) (P=0.016). Multivariable Cox-regression identified a prior solid organ transplant (OR:5.2; P=0.002), higher pathologic-stage (OR:3.8; P=0.03 for pT2, OR:3.6; P=0.04 for pT3, OR:4.5; P=0.03 for pT4), and administration of "any systemic treatment" (OR:0.3; P=0.001) as OS predictors. For CSS, predictors were a prior solid organ transplant (OR:3.0; P=0.03), higher pathologic-stage (OR:9.8; P=0.04 for pT3, OR:13; P=0.02 for pT4), and administration of "any systemic treatment" (OR:0.4; P=0.03). CONCLUSIONS: Solid organ transplant recipients undergoing RC and PLND for urinary UBC have worse survival outcomes compared to non-SOTRs. Our findings may impact patient counseling, follow-up, and planning future clinical trials.
Department of Pathology Medical University of Vienna Vienna Austria
Department of Urology 2nd Faculty of Medicine Charles University Prague Czech Republic
Department of Urology Comprehensive Cancer Center Medical University of Vienna Vienna Austria
Department of Urology Croix Du Sud Hospital Quint Fonsegrives France
Department of Urology Santa Maria delle Croci Hospital Ravenna Italy
Department of Urology University of Texas Southwestern Dallas TX USA
Division of Urology IRCCS University Hospital Bologna Italy
Hourani Center for Applied Scientific Research AI Ahliyya Amman University Amman Jordan
Karl Landsteiner Institute of Urology and Andrology Vienna Austria
Citace poskytuje Crossref.org